Findings

What do systematic reviews say?

27 questions · 27 findings · 14 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 9 · 33.3%GRADE not reported 0 · 0%Very low 6 · 22.2%Low 6 · 22.2%Moderate 6 · 22.2%High 0 · 0%

Psychological therapies vs no intervention

QoL · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 348 participants
Very low

Oral azithromycin vs placebo

QoL · adults and children with cystic fibrosis

1 finding from 1 review

Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes only
no estimate extracted
1 study · 177 participants
Moderate

Summary of findings: inhaled antioxidants vs placebo

Quality of life: change in CFQoL score from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Antioxidant supplementation for lung disease in cystic fibrosis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 153 participants
Moderate

Psychological therapies vs education

Quality of life (emotional) · patients with chronic obstructive pulmonary disease

1 finding from 1 review

Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 460 participants
Very low

Flutamide 250 mg once to b.i.d. vs spironolactone 100 mg

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Ethinyl estradiol 35 μg + cyproterone acetate 2 mg vs ethinyl estradiol 30 μg + desogestrel 0.15 mg

Change in health‐related quality of life (HRQOL) ‐ not measured · patients with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Spironolactone 100 mg vs placebo

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Finasteride 5 mg to 7.5 mg vs placebo

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin 500 mg to 2550 mg per day vs placebo

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Finasteride 5 mg vs spironolactone 100 mg

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Flutamide 250 mg once to b.i.d. vs metformin 1275 mg to 1700 mg per day

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Finasteride 5 mg vs flutamide 250 mg once to b.i.d.

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Flutamide 250 mg b.i.d. vs placebo

Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for hirsutism (excluding laser and photoepilation therapy alone) 2015 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cilostazol vs placebo

Quality of life (change in points, SF‐36, WIQ) · intermittent claudication

1 finding from 1 review

Cilostazol for intermittent claudication 2021 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 1163 participants
Low

Intervention not reported

Change in quality of life Measures: QWB, HAQUAMS, MSIS‐29, SF‐36, LMSQOLS, · People with multiple sclerosis

1 finding from 1 review

Telerehabilitation for persons with multiple sclerosis 2015 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 392 participants
Low

Summary of findings: Molecular‐targeted therapy plus chemotherapy vs chemotherapy alone

Health status and quality of life · people with advanced gastric cancer

1 finding from 1 review

Molecular‐targeted first‐line therapy for advanced gastric cancer 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 53 participants
Very low

Summary of findings ‐ dual therapy: lumacaftor plus ivacaftor (once daily) vs placebo

Quality of life ‐ (EuroQol) EQ‐5D‐3L Index Score (total score): absolute change from baseline · adults and children with cystic fibrosis

1 finding from 1 review

Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1061 participants
Moderate

Self‐management interventions vs usual care

Quality of life Change scores/post intervention SF‐12 or ‐36: physical or mental functioning EuroQol; SAQoL; SSQoL · people with stroke

Self management programmes showed no clear difference in quality of life Change scores/post intervention SF‐12 or ‐36:… compared with usual care (low certainty).

1 finding from 1 review

Self management programmes for quality of life in people with stroke 2016 · Cochrane Headline outcomes only
SMD 0.2 [0, 0.41]
6 studies · 469 participants
Low

Topical antibiotics with steroids vs topical steroid

Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life · people with eczema

1 finding from 1 review

Interventions to reduce Staphylococcus aureus in the management of eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 42 participants
Moderate

Oral antibiotics vs placebo

Change from baseline in quality of life IDQoL ranges from 0 to 30 with higher values indicating more impaired quality of life. · people with atopic dermatitis

1 finding from 1 review

Interventions to reduce Staphylococcus aureus in the management of eczema 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 45 participants
Moderate